Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-15
2006-08-15
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S060000
Reexamination Certificate
active
07091238
ABSTRACT:
The invention discloses a compound having the formula (I) wherein R1is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, unsubstituted phenyl, and substituted phenyl; R2is selected from the group consisting of H, alkene, un-substituted phenol, and substituted phenyl; and pharmaceutically acceptable salts thereof, having digitalis-like properties. The invention further discloses a novel method to synthesize 3,4-methylenedioxybenzoyl-2-thienylhydrazone (LASSBio-294). LASSBio-294 produces positive inotropic effect on cardiac and skeletal muscle. The invention is useful for the treatment of congestive heart failure and muscle fatigue. It lacks toxic effects seen in digitalis glycosides.
REFERENCES:
patent: 0 079 050 (1983-05-01), None
patent: 0 219 112 (1987-04-01), None
Van Heeswijk, PubMed Abstract (Ther Drug Monit. 24(3):323-31) Jun. 2002.
Marcus et al., PubMed Abstract (Intervirology 45(4-6): 260-6), 2002.
Simone, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Singh et al., Immune therapy in inflammatory bowel Disease and models of colitis, British Journal of Surgery, 88:1558-1569, 2001.
Robinson, Medical Therapy of Inflammatory Bowel Diseases for the 21stCentury, Eur. J. Surg. Suppl. 582:90-98, 1998.
Bremmer et al., Therapy of Crohn's disease in childhood, Expert Opin. Pharmaceuticals. 3(7): 809-825, 2002.
Beers et al., Crohn's Disease & Ulcerative Colitis, The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, Section 3, Chapter 31, 1999.
Koren, Diastolic Congestive Heart Failure, Jacksonville Medicine, Feb. 2002.
Lerman, Endothelial Dysfunction and Ischemia, Oct. 2002.
Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400 (1992).
Bundgaard, Design of Prodrugs, p. 1, 1985.
Kucukguzel, et al. “Synthesis and antimycobacterial activity of some coupling products from 4-aminobenzoic acid hydrazones” European Journal of Medicine, Chem. Chim. Ther., (Dec. 1999) vol. 34, No. 12 pp. 1093-1100.
Mazzone et al. 2-Pyridyl-5-alkoxyphenyl—1, 3,4-thiadiazo les by the action of sulfur on methylpyridines in the presence of alkoxyhydrazines, J Heterocyclic Chem. (1984) vol. 21 pp. 181-184.
Mazzonw et al., Su alcuni aroilidrazoni di alogenobenzaldeidi e 2,5-diaril-1, 3, 4-ossdiazoli alogeno-sostituiti II Farmaco, (1978) vol. 33, pp. 963-966.
Tihany et al. “Pyrazolecarboxylic acid hydrazides as antiinflammatory agents. New selective lipoxygenase inhibitors” European Journal of Medicine -Chem. Chim. Ther., (1984) vol. 19, No. 5 pp. 433-439.
Albuquerque Edson X.
Aracava Yasco
Cintra Wagner Monteiro
Da Silva Claudia Lucia Martins
De Barreiro Eliezer J.
Rao Deepak
University of Maryland
Venable LLP
Wiseman Thomas G.
LandOfFree
Thienylhydrazon with digitalis-like properties (positive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienylhydrazon with digitalis-like properties (positive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienylhydrazon with digitalis-like properties (positive... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3694595